AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03768674 — intervention group
Intervention type: OTHER
Intervention: Assessment of diagnoses, functioning and health services
Description: Systematic differential diagnostics, assessment of psychosocial and personality functioning and treatment/ health services
Study NCT02642679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opticell Ag
Description: Opticell Ag+ applied to STSG donor site
Study NCT02920853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback Training (BT-CPR)
Description: Participants will receive biofeedback training (which will include electric stimulations) to reduce arousal and pain
Study NCT03332953 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: E-cigarettes with varying concentrations of nicotine & flavor
Description: Subjects will be asked to vape various e-cigarettes containing e-liquids at three concentrations of nicotine and sweet flavor (9 stimuli per subject).
Study NCT01758601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood
Study NCT01758601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood
Study NCT01323491 — intervention group
Intervention type: DRUG
Intervention: Nicotine replacement therapy
Description: Nicorette® TX tape 10mg, 15mg, 25mg Nicorette® microtab 2mg Nicorette® inhaler 10mg Nicorette® chewing gum 2 mg, 4mg freshfruit, freshmint, mint, whitemint
Study NCT02773992 — intervention group
Intervention type: BEHAVIORAL
Intervention: The IoT
Description: For the IoT group, three plus two type pulmonary nodule diagnosis： ① gather information: smoking history, tumor personal and family history, copd history, etc.; ② noninvasive examination: tumor markers, lung function and chest low-dose CT thin layer; ③ information mining in-depth:through the software for three-dimensional reconstruction of pulmonary nodules, depth excavation, accurate calculation of the density of the volume, assessment of the surrounding and infiltration of lung nodules and related vascular growth status; two solutions: ① Pathological diagnosis in highly suspected patients: fiber bronchoscope, ultrasonic bronchoscope, thoracoscope and CT guided percutaneous lung biopsy, etc.; ② Close scientific follow-up to the person who can not be qualitative: doctors follow up and manage patients scientifically in accordance with the follow-up management tables through the Internet of things platform.
Study NCT02487745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence-contingent wage supplements
Description: Before obtaining competitive employment, participants will be able to earn wage supplements for attending two individual placement and support (IPS) supported employment sessions per week, and for completing specific tasks prescribed by IPS including developing a worker profile, applying for appropriate jobs, and completing job interviews. Once a participant becomes employed, participants will be able to earn up to $5 per hour for every hour worked in a competitive job up to 40 hours per week verified by pay stubs. To maintain long-term drug abstinence, participants will be required to provide urine samples to earn the maximum in wage supplements.
Study NCT02487745 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Placement and Support (IPS) supported employment
Description: Individual Placement and Support (IPS) supported employment involves rapid job search, promotes competitive employment, considers the participant's preferences, and provides job supports and benefits counseling. An employment specialist will establish relationships will potential employers and work with participants to identify potential jobs, prepare applications, and to apply for positions.
Study NCT02487745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) supported employment
Description: Individual Placement and Support (IPS) supported employment involves rapid job search, promotes competitive employment, considers the participant's preferences, and provides job supports and benefits counseling. An employment specialist will establish relationships will potential employers and work with participants to identify potential jobs, prepare applications, and to apply for positions.
Study NCT00170677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan 4,0 mg/m² administered in day 1, 8 und 15 as i.v. infusion for 30 minutes. A cycle lasts 28 days.
Study NCT00170677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan 1,25 mg/m²/day, day 1-5 as i.v. infusion of 30 minutes. Repeat after 21 day.
Study NCT00917020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal CO2
Description: As-Needed during the 14 day Treatment Period
Study NCT00917020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Placebo Gas
Description: Placebo
Study NCT02176525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA
Study NCT02176525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01216085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose imatinib
Description: Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
Study NCT03611335 — intervention group
Intervention type: BEHAVIORAL
Intervention: CATCH Interviews
Description: Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)
Study NCT03621995 — intervention group
Intervention type: OTHER
Intervention: Malondialdehyde and Catalase level measurement
Description: Malondialdehyde and Catalase level measurement by colorimetric method
Study NCT01030042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX-4
Description: Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
Study NCT02920853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback Training
Description: Participants will receive biofeedback training to reduce arousal and pain
Study NCT03894592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: Trauma patients enrolled in the study will be offered Virtual Reality experieince per the protocol
Study NCT03790007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: In our study this local anesthetic agent will be applied for postoperative pain relief
Study NCT02403388 — intervention group
Intervention type: OTHER
Intervention: PRisM
Description: A risk management program for each professional of care in multiprofessional primary care offices in France.
Study NCT04163731 — intervention group
Intervention type: OTHER
Intervention: DASI questionnaire
Description: All patients who accept to participate will undergo a self-questionnaire of 10 minutes. Medical data of their cardiac stress test and risk factor will be collected.
Study NCT01251146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Bisoprolol will be administered at a dose of 5 milligram (mg) once daily for 2 weeks. If heart rate is less than or equal to 65 beats per minute (bpm), then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 7.5 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate is still greater than 65 bpm, then the dose will be further increased to 10 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
Study NCT01251146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Atenolol will be administered at a dose of 50 mg once daily for 2 weeks. If heart rate is less than or equal to 65 bpm, then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 75 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate still greater than 65 bpm, then the dose will be further increased to 100 mg once daily for 2 weeks. After 2 weeks, If the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
Study NCT02810678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Latent Tuberculosis Infection program evaluation & diagnosis
Study NCT00607932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention
Study NCT00607932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brassica vegetable
Study NCT00607932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indole-3-carbinol
Description: follow up at 2,4,6 months post baseline.
Study NCT00607932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: 2, 4, 6 months post baseline
Study NCT02632253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIIT
Description: High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. The HIIT group will perform two supervised HIIT trainings and one self monitored MICE training per week.
Study NCT02632253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MICE
Description: MICE is also performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform two supervised and one self monitored MICE training per week.
Study NCT00101439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Study NCT00101439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Study NCT01030042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan/Cetuximab
Description: CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.~IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression.
Study NCT02694029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Breathing Coordinator (ABC)
Description: The ABC system has a digital spirometer that records real time breathing. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH
Study NCT02694029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisionRT
Description: A technology for implementing the deep inspiration breath-hold technique is real-time surface photogrammetry. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH.
Study NCT04569539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound scan of the cricothyroid membrane
Study NCT01516801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSA flyer
Description: A mailed low-literacy informational patient flyer about the PSA test
Study NCT03721107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blautix
Description: Blautix is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen was two capsules two times per day for the duration of the treatment period.
Study NCT03721107 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study NCT06436521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Cognitive Behavioral Therapy
Description: Positive CBT integrates brief Solution-Focused Brief Therapy with Positive Psychology techniques, within a cognitive-behavioral framework. It is considered a competency and strengths-based model.
Study NCT06436521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Cognitive Behavioral Therapy
Description: Traditional cognitive behavioral therapy is a form of psychological treatment that emphasizes that psychological problems are based on faulty or unhelpful ways of thinking and the focus is to change thinking patterns.
Study NCT03491085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/clavulanate
Description: after tonsillectomy half of our patients will receive Amoxicillin /clavulanate for one week and the other half will not receive it.
Study NCT01570582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin and paclitaxel
Description: Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.
Study NCT02294019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg caplet
Description: 400 milligram (mg) caplet according to Drug Facts label
Study NCT04697147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conscious Discipline-Based Environmental Enrichment Intervention
Description: Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
Study NCT01275248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Oral tablets in 0.5mg or 0.75mg strength
Study NCT01275248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet to match the experimental interventions
Study NCT00855712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Organ Care System
Description: The Organ Care System (OCS) is a portable organ perfusion and monitoring system intended to preserve a donated heart in a near normal physiologic beating state during transport for eventual transplantation into a recipient. The OCS maintains organ viability by providing a controlled environment that simulates near-normal physiological conditions, continuously perfusing the donated heart with warm, oxygenated blood, supplemented with the Solution Set. The blood is collected from the donor and continuously circulated to the organ in a closed circuit along with the Solution. The OCS preserves and monitors the organ's perfusion and metabolic state after explantation from a donor and connection to the device, during transportation to the recipient site, and until disconnection from the device.
Study NCT00855712 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Cardioplegia Solution
Description: This is the standard of care solutions used to arrest and preserve the donated heart during transport until arrival at recipient hospital
Study NCT02383329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml
Description: The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml
Study NCT01975025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short daily dialysis for 2 weeks
Study NCT02443844 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection
Description: Endoscopic treatment of bladder cancer
Study NCT02443844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Medical treatment for benign prostate hyperplasia
Study NCT00360022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint visits
Description: Both the pediatric GI specialist and the adult GI specialist will see the patient together at 2 different visits. The first joint visit is lead by the pediatric MD and the second joint visit is lead by the adult MD.
Study NCT03876340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment algorithm
Description: Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures. The thermograms will be used to dictate the initial treatment.
Study NCT03876340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current treatment
Description: Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures, but the results will be kept sealed until the study is finished. The patients will receive the usual standard of care as dictated by the surgical team.
Study NCT06013787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nuestras Historias
Description: Nuestras Historias is a digital story curriculum that is displayed on a small solar-powered tablet. The curriculum is a collection of 7 digital stories used to discuss health issues during pregnancy that the community identified as important. The digital stories are short videos that combine local photos and local voices sharing real-life narratives about experiences during pregnancy. The videos were made in collaboration with community health workers and local mothers.
Study NCT04110834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole gel once daily
Description: itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
Study NCT04110834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole gel twice daily
Description: itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
Study NCT04110834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, itraconazole, is not added then applied twice daily in the same manner
Study NCT00353457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Oxaliplatin and Cetuximab
Description: Capecitabine 825mg/m2 po BID D1-15 of 21 x2 cycles (Cyle 1 and 2), Capecitabine 825mg/m2 po BID weekly Sun PM-Fri AM x2 cycles (cycle 3 and 4), Capecitabine 825mg/m2 po BID D1-15 of 21 x4 cycles (cycle 5,6,7,8) Oxaliplatin 130mg/m2 IV Day 1 every 3 weeks x2 cycles (Cycle 1 and 2), Oxaliplatin 50mg/m2 IV weekly every Monday x2 cycles (Cycle 3 and 4), Oxaliplatin 130mg/m2 IV day 1 every 3 weeks x4 cycles (Cycles 5,6,7,8) Cetuximab 400mg/m2 IV cycle 1 day1, Cetuximab 250mg/m2 Day 1,8,15 of 21 for cycles 1-8
Study NCT00353457 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 45 Gy in 25 fractions, 3-fraction boost 5.4 Gy
Study NCT00852696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.
Study NCT00852696 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take orally once daily for 9 weeks.
Study NCT03801707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]
Description: fixed dose combination medication once a day for 12 weeks for the treatment of hepatitis C
Study NCT03801707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
Description: Three tablets once a day for 12 weeks for treatment of hepatitis C
Study NCT02637141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 714
Description: AMG 714 administered by subcutaneous injection
Study NCT02637141 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to AMG 714 administered by subcutaneous injection
Study NCT02637141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Gluten Challenge
Description: Gluten-free cookies (Finnish rusks)
Study NCT01509209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine / Levocetirizine
Description: tablet, BID everyday
Study NCT01509209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pseudoephedrine / Levocetirizine
Description: tablet, BID everyday
Study NCT00290420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine profilaxis
Description: Prevention:~Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes
Study NCT00562107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symphony DR 2550 and REPLY DR cardiac pacemakers
Description: AAISafeR/SafeR ON